Form PTO-1595 RECORDATION FOR (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002) Tab settings □ □ □ □ ▼ ▼ ▼	U.S. DE: ARTMENT OF COMMERCE U.S. Patent and Trademark Office		
To the Honorable Commissioner of Patents and Trademarks	: Please record the attached original docum ants or copy thereof.		
Name of conveying party(ies): Nabi Biopharmaceuticals	2. Name and address of receiving party(les) Name: Wells Fargo Foothill, Inc. Internal Address: Attn: Business Finance Mgr.		
Additional name(s) of conveying party(ies) attached? Yes 💉 No			
Nature of conveyance:	-		
Assignment Merger Security Agreement Change of Name Other_Supplement to Patent Security Agreement	Street Address: 400 North Park Town Center 1000 Abernathy Road, Suite 145		
	City: Atlanta State GA Zip: 30328		
Execution Date: November 17, 2003	Additional лате(s) & address(es) attached? Yes 🔽 No		
If this document is being filed together with a new appli A. Patent Application No.(s) 10/279,598	B. Patent No.(s) 4,870,105 6,576,665		
Additional numbers at	tached? Yes V No		
Name and address of party to whom correspondence concerning document should be mailed: Name: David Postolski Internal Address: Schulte, Roth & Zabel LLP	6. Total number of applications and patents involved: 3 7. Total fee (37 CFR 3.41)		
Street Address: Schulte, Roth & Zabel LLP 919 Third Avenue City: New York State: NY Zip: 10022	8. Deposit account number: 500675 - Schulte, Roth & Zabel		
DO NOT USE THIS SPACE			
9. Signature. Barbara Bauer-Padron Name of Person Signing	Signature December 1, 2003		
Total number of pages including cover	sheet, attachments, and documents:		

Mail documents to be recorded with required cover sheet information to: Commissioner of Patents & Trademarks, Box Assignments Washington, D.C. 20231

SUPPLEMENT (PATENTS)

This is a supplement (the "Supplement (Patents)") to the Patent Security Agreement (the "Agreement"), dated as of June 18, 2003, between NABI BIOPHARMACEUTICALS, a Delaware corporation (the "Debtor"), in favo of WELLS FARGO FOOTHILL, INC., a California corporation, as the arranger and administrative agent for the Lenders (the "Secured Party"). Capitalized terms not defined herein shall have the meaning set forth in the Agreement.

Pursuant to Section 6 of the Agreement, Debtor hereby provides notice that Debtor has acquired the following Patent Collateral constituting Material IP:

COUNTRY	PATENT/ SERIAL NUMBER	FILING/ ISSUE DATE	STATUS	TIFLE
Canada	1,333,884	1/10/95	Issued	Phosphorus B nder
U.S.	4,870,105	9/26/89	Issued	Phosphorus B nder
U.S.	6,576,665	6/10/03	Issued	Encapsulated Calcium Acetate Caple: and a Method for Inhibiting Gastrointestinal Phosphorous Absorption
U.S.	Serial No. 10/279,598	10/24/02	Pending	Encapsulated Calcium Acetate Caple and a Method for Inhibiting Bastrointestinal Phosphorous Absorption

The above patents are collectively referred to herein as the "Supplemental Patents" and constitute "Patent Collateral" pursuant to the Agreement.

NOW, THEREFORE, for valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Debtor hereby reaffirms its grant pursuant to the Agreement of, and hereby grants to the Secured Party for the benefit of the Lender Group, a continuing, first priority security interest in all of the Debtor's right, title and interest in, to and under the Supplemental Patents and the inventions that are the subject of the Supplemental Patents, with such security interests consistent with, and subject to the terms and conditions set forth in, the Agreement. For each Supplemental Patent, the effective date of Secured Party's security interest in such Supplemental Patent shall be the date such Supplemental Patent was acquired by Debtor.

Debtor does hereby further acknowledge and affirm that the rights and remedies of the Secured Party with respect to the Supplemental Patents are more fully set forth in the Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein.

[Signature page follows]

PATENT REEL: 014438 FRAME: 0330

120×

DEBTOR:

NABI BIOPHARMACEUTICALS, a Delaware corporation

By:

Name: Mark Smith

Title: Chief Financial Officer Date: November 17, 2003

SECURED PARTY:

WELLS FARGO FOOTHILL, INC., a California corporation

By: _____

Name:

Title: Date:

PATENT REEL: 014438 FRAME: 0331 2125935955 SCHULTE ROTH & ZABEL LLP (WED) 3. 17'04 18:15/ST. 18:13/NO. 4261294411 P 5

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, as of the date(s) set forth below.

\mathbf{DEB}	TOR:

NABI BIOPHARMACEUTICALS, a Delaware corporation

By:

Name: Title: Date:

SECURED PARTY:

By:

WELLS FARGO FOOTHILL, INC.,

a California corporation

Name:

Title: Date: (0-22 BB)

9504028.1

1273840.1

9504028.1

[SEAL]

STATE OF)	
COUNTY OF) ss)	
	at and acknowledged to me that (ies), and that by his/her/their sehalf of which the person(s) act	rsonally known to me (or on(s) whose rame(s) is/are he/she/they executed the same ignature(s) on the instrument
[SEAL]	Signature	
STATE OF Georgian COUNTY OF FULLON On Addit 22,)) ss) 2003, before me, <u>Process</u> E	Motary , Notary
Public, personally appeared <u>Den</u> proved to me on the basis of satisf subscribed to the within instrumer in his/her/their authorized capacity the person(s), or the entity upon be	actory evidence) to be the person at and acknowledged to me that ((ies), and that by his/her/their s	on(s) whose r ame(s) is/are he/she/they executed the same ignature(s) on the instrument
WITNESS my hand	1 and official seal.	
[SEAL]	Aleins E. Signature	(de)

9504028.1

PATENT REEL: 014438 FRAME: 0334

RECORDED: 03/17/2004